Reducing Transfusion-Related Costs and Time With Pacritinib Among Patients With MF
Key Takeaways:
- In an economic evaluation of the PERSIST-2 clinical trial, pacritinib was associated with significant reductions in transfusion-related costs and time compared to best available therapy among patients with myelofibrosis (MF).
- Compared to best available therapy, patients treated with pacritinib had decreases of 19.5% and 25.3% in annual transfusion-related costs and time, respectively.
- Reductions in cost and time were observed across varying levels of severity, highlighting the clinical efficacy of pacritinib regardless of disease progression.
Anemia is a common comorbidity among patients with MF, with red blood cell (RBC) transfusions being the primary treatment method. However, frequent transfusions can create a substantial economic burden among patients.
The PERSIST-2 clinical trial compared the transfusion burden and efficacy of pacritinib against best available therapy among patients with MF. In this study, pacritinib demonstrated meaningful clinical benefits and lowered transfusion dependence, suggesting it may also decrease transfusion-related costs and time.
Study Methods and Outcomes
Researchers conducted an economic analysis using data from the PERSIST-2 trial to estimate projected differences in transfusion-related costs and time between pacritinib and best available therapy.
The study assessed 180 patients, 92 treated with pacritinib and 88 treated with best available therapy. Approximately 47% were non-transfusion-independent (TI) at baseline.
Pacritinib Associated With Reduced Cost and Time Burden
Patients receiving pacritinib had 19.5% lower annual transfusion-related costs compared to those receiving best available therapy, $252 057 vs $312 969, respectively, resulting in per-patient cost savings of $60 912. Pacritinib was also associated with cost savings of $73 095 among patients who were non-TI at baseline.
Pacritinib reduced the annual transfusion-related time burden by 25.3% compared to best available therapy, 507.9 vs 680.4 hours, respectively, saving each patient a total of 172.4 hours. Projected time savings were higher among patients who were non-TI at baseline as well, reducing the time burden by 204.3 hours for patients with pacritinib compared to best available therapy.
Fewer RBC transfusions, less recovery time, shorter waiting time for blood availability, and reduced travel time were the main drivers of savings among patients treated with pacritinib.
Significant savings in transfusion-related costs and time were observed across different levels of disease severity. Although patients with increased severity required frequent transfusions, pacritinib was still associated with burden reductions among patients with higher platelet counts and Dynamic International Prognostic Scoring System (DIPSS) scores.
Economic and Clinical Benefits of Reduced Transfusion Dependence
This economic analysis of the PERSIST-2 trial found that pacritinib was associated with significant transfusion-related cost and time savings compared to best available therapy among patients with MF.
By decreasing the need for transfusions, pacritinib led to substantial reductions in corresponding medical costs and transfusion-related activities. In addition, 37% of patients treated with pacritinib in the PERSIST-2 trial who were non-TI at baseline achieved TI status by the study’s end, further demonstrating the medication’s effectiveness in reducing transfusion dependence.
Overall, these findings illustrate the potential of pacritinib to reduce the economic and time burden among patients with anemic MF, regardless of disease severity.
Reference
Gerds AT, Oladapo A, Roman-Torres K, Oh ST. Transfusion-related cost and time burden offsets associated with pacritinib versus best available therapy in patients with myelofibrosis: an economic evaluation based on the PERSIST-2 trial. Future Oncol. 2026:1-9. doi:10.1080/14796694.2026.2760147


